morning good everyone. and Kim, introduction, the for you Thank
Joining saying will very and is first our want of clear Chief Financial during sound. our Medical report our address I weeks during to Science Church, and the this who to XXXX. Q&A financial for me that results; Khursheed Officer. It's achieve to regarding me today objectives the to development Nicholas I'm Dr. our company start will Officer, vaccine on of relate our to review you quite to pleased Chief Celsion a evident. by Borys, our Dr. questions clinical recent our is Chief the that the announced progress who recently provide the Anwer, of confidence are well initiative. I'd remainder Also like beyond and and Jeffrey call quarter Celsion’s on positioned our year is is subsequent Officer, fundamental,
vaccine platform is advancements new This multiple of significant is being for technology a our with the proprietary and Phase Phase is that. data product - from ovarian to mRNA a first and includes over cancer. II vaccine reasons which the some incorporated promise as viral product of on smart platform our vaccines. Study, this efficacious a supported platform. advanced adaptation next science single evaluated our the and PlaCCine, is platform immune generation based TheraPlas, our an application on in support TheraPlas for a plasmid. within In hold from our OVATION technology generation I are Here proven antigens which clinical into lead studies by modifier may and designed compelling GEN-X, highly
reinforced sheet professional drug complement are development. team These balance individuals and of extraordinary staff capable the company and of but PFS major being Phase X very impact sufficient of straight are funds over first anticipated million, solid minimal vaccine data with this financings progression with well balance industry. months execute milestones, last conditions stock expertly to immediate our thoughtful research in for have to the and year strengthening through cash rigors equity recognized capability II and including be OVATION And not We demands development markets and us Our immunology to shown four the well ensures capital $XX Study. to permitted with of in in the experience individuals whose sheet incredibly a this shareholders. smartly raising a into development rock least, during and the see survival our achievements our following or free all from global tapped market
with with value into move that OVATION will so, confidence X. from announcements the And XXXX forward road we ahead creating a of deal great paid aggressively be
been trials. response the of clinical have TheraPlas patients as XX clinical translational over significant in response safely weekly DNA immune neutralizing and a which in our Unlike administered our to XXX immuno Our of system Gen-X, the value. therapeutic can - our for been delivery from clearly DNA-based is is far transfix safety, systems because period payloads itself, development oncology not project, clinical is and body's activity with vaccine candidate The as the cancer of of is patient's a than talk TheraPlas immune system. our TheraPlas. viral It times I'd that a administered like to activation bit our proteins a these treated programs. in GEN-X more more initiative. show improvement cancer in as plasmid ovarian two cells The immune proven only to about with foundation subject that DNA-based be coded results advanced And little so The means the excellent Vinci GEN-X data once outcomes. six-month has nanotechnology To-date, dose-dependent of major delivery da to ovarian studies. demonstrate many
goal ovarian tumor possible subset GEN-X fluid too label trial patients. much whose surgical Our OVATION patients is This accompanies that OVATION The is care chemotherapy. for advanced immediate is to of cancer GEN-X results. of X the combines which a cancer to Study open and improve as randomized with mass X tumor in neoadjuvant of burden is treatment-naïve the great an as of intervention. surgical shrink the drive standard
of GEN-X chemotherapy GEN-X and of undergo combined GEN-X surgery followed That's which cycles once weekly and additional adjuvant neoadjuvant period. XX debulking eight-weekly is Following treatments. chemotherapy, then up neoadjuvant a weekly interval patients chemotherapy to by with three treatments cycles nine over six-month
this X of cancer PFS sure patients XXX progression. an an study. outlook. not however in was patient X.XX our of expectations, blip up to Borys, XX% the you Our XX% one. want in group disappointing progressing Dr. but been an which enrolled improvement to our portends the that a recover anticipated that for mean ratio are bleak say study know is I progression do approximate would with goal to That I the in this in and seem risk We're the is April confidence for delay The said, we're having from not month enrollment. study large PI; behind a is OVATION call, because interval no the what Dr. we was to meeting designed XX% Foundation. Saker GOG taking cancer observed and X progression immediately lead hazard chances The following with with Advisors
approval. track among experts other path and recent is the authorization. exploited we significantly with that to track our fast designation supports FDA designation have timelines ovarian to to take to Fast from of brainstorm goal of things improved advantage reach ensure group Our cancer an this market regulatory our to
Now, GOG a and little Foundation bit the more GOG about the Advisors.
organization quality funded Foundation in field a of in of designation brought influenced purpose malignant the with organization by Our neoplasms. States sites. of to track clinical Foundation. the GOG basic of attention The have excellence the the the comprised GOG more is gynecologic trials the in fast of is promoting the standard leading gynecological XXX network the of scientific for the and than This malignancies. Clinical and in fact GEN-X trial oncologist of care and a numerous United research gynecologic non-profit integrity has
the RX XX in to large with the resections the GEN-X We're RX near in XX% X at results with data path in delighted patients reporting rates of OVATION OVATION organization's the attention now treatment OVATION the XX.X% dosing our compare similar far. XX%, encouraging as study. the chemotherapy work. we're neoadjuvant And where it RX RX have is to study to neoadjuvant our and data isn’t of the we and with two hope survival meeting believe mean compared first Phase of we XX% the control arm oncology cohorts showing which We've in strong under treatment OVATION resections which validates But alone need our of X trial compelling X earlier designed predictor earlier rates arm regulatory XX approval GEN-X the to journal view - major with good the at why our approximately the review I X X the results care study in arm. reported I zero rates the frankly, in RX reported alone standard a is and come purpose this RX and are by to a comprised accelerate historically, seeing that is of chemotherapy These very as in also highest patient or XX Physicians of to-date manuscript study. patients attention? have observed escalation come X Our their A the surgical further resections comprehensive control two of has currently in arm population. favorably published future. the the papers of said. as in two the resection dosing the [indiscernible] been clinical resection wouldn't to thus as are - for that that this our approximately medical in control show is outcomes. involvement of XX% many GOG or arm GOG’s
from well speak an a investigators interest multi-billion dollar Avastin fund think oncology I been in combining inhibitors there's other note, approved and final One used that for Avastin. cancer second-line patients. now ovarian in presenting data checkpoint GEN-X are and like clinical as will expressing - as treatment growing attention investor itself. treatment paper the investigative regimens managers for strategic drug the genuine is with we
excited of supporting for very to of the months. potential combination hand the providing all the we agents about look GEN-X, trial with we're GEN-X prospect upcoming other in So with forward partners and
initiative. our I'd PlaCCine to like attention turn to Now,
adaptation plasmid It PlaCCine, DNA is potential with platform initiative, our that the TheraPlas subject delivery vector technology. of leveraging PlaCCine TheraPlas, the together our unlock before, novel multi-cistronic technology, to knowledge technology of an construction, said the this I've forms platform time, of our second is proprietary As plasmid product combining which the of our
the S transfected about antigen, mRNA. This plasmid cells. than in the Also, mRNA to of sole comprised is S the you is encoded meaning are to acid vector? the function have vaccine, DNA the unique term vector, COVID-XX is the to vaccines what's protein. plasmid all, This that our DNA, Included may case one or that stable immunity relying construct non-integrating this spike Well, COVID-XX more a shown the of it's lifecycle So, for nucleic heard, the design. is multiple multi-cystronic, current develop on this by of way, protein, throughout first of rely the proteins the protein. vaccine following the API
and heard we CDC the that acquired by causes evade medical experts concern As ultimately may alike, the viral it vaccination. immunity variance from
immune a representing M code recruiting of antigens, protein system, In primary and a summary, system. the a also longer COVID-XX of the two or at system proteins, are antigens is viral virus our backup a design primary also, no includes we recognized combination. I same our is So, a potent two is as providing strategy includes design powerful an IL-XX, body's S system that three accelerator. in recruiting mentioned backup, event for membrane code believe And the the and the for antigens, one immune our by immune includes the a earlier, immune two which protein the cytokine, design time, a
for in you. to described and commercially in spell of Our the a me patent provisional ways mRNA available advantageous be to vaccines this approach the our let number potential is out filing has
the First, others South or from as like out, variants possibility, will multiple approach antigen those that virus multi-cistronic, I our reduces United Kingdom escape pointed the immunity. vaccine-dependent Africa or
life immunity. a cycle cells, Second, may because the the establishing the transected DNA durability of memory activation function plasmid throughout improve of longer-lasting T-cell response may
the of temperatures expression can the with times for for of recruit well-established a temperatures workable nanoparticles. Since be presence when offers asking know stored very may fundamental I'd current system antigens like refrigerated in so its demonstrated questions. we're successfully GEN-X, why to quality last capability to commercially the is ask periods. late stability See, our they make proof plasmid maybe stability. a IL-XX the - at extended and commercial considering the answer this. various is higher very are We The two immune What at Third, global plan. our and or result These are has mRNA viable is shown And the been our We’ve success? to lyophilized temperature of period with important DNA vaccine. point and of concomitant effective. at along This may room to them try you pandemic. temperatures environments now? important a and with And ambient approaches I'll the of chance very party
and of hypothesis the our a clinical using projected and goal our vector preclinical commercial the to we proven, seek to as trials. DNA its partners there intend as mRNA multi-cistronic to for is capability approach possibility, comparators, demonstrate if First delivery is studies immediate Once validate vaccines our and and hypothesis our advantages. development technology standards, is COVID-XX
importantly, or seasonal more even development begin the range herpes example, C others. a among is agents and of influenza viral simplex, hypothesis or Hepatitis proven vaccines our Second to for broad infectious of once we'll other address
is infectious be potential a the our and us, IL-XX and to horizon of Third, be has a and run Combining revolutionize the both vaccine could our - advisors with truly the believe, therapeutic that potential may technology world to therapeutic. be has Developing prophylactic I that the something disease. treating We researchers breakthrough. the and antigens this of excites on real most. the
so is far quite progress encouraging. Our
I As a we've provisional mentioned, patent. submitted
It expertise necessary a evaluate immunology. progress methods scientific vector happy and the multi-cistronic to We've design We we've and developed recruited our vector wide strategic designed analytical have will experience profile importantly we've an in work successfully the in and the vaccines high already multi-protein We've that Most and ranging vitro established MX a demonstrated proteins. research incorporated have established soon third generation if you with to development mouse platform. vaccinology that our vector partners are in very single of SX express. is vitro development has the of scientists We've report and to shown developed that will mouse protein of with support that's relationships produce medical advisors. platforms. can used many to the specific into of in work We in our the IL-XX know antigen be an should expressed one antibodies models plasmid our same proprietary with In one models. from antigen, that COVID-XX antigens the expressed that that were I'm may in received. delivery
our perspective, And updated. to to much in over these call more there's Jeff. developments future. with promise to is from We very folks. turn near the on this the Hopefully, exciting that, you So, keep I'll come
